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Abstract 
Non-traceless modified Staudinger reaction was utilized as a safe method in this 
work to synthesize novel synthons of UDP-N-acetyl-L-fucosamine as potential inhibitors 
of or substrates for bacterial glycosyltransfares, responsible for the biosynthesis of the 
capsular polysaccharide of Staphyloccous aureus. Carbon-13 and proton spectral 
techniques were used in the characterization of formed products. 
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INTRODUCTION 
Staphylococcus aureus, a Gram-positive bacterium, has the ability of residing in 
the human body without causing any harm. However, this particular pathogen is also 
responsible for a large portion of hospital and community-acquired infections globally. 
These includes superficial skin and soft tissue infections, deep wound and internal organ 
infections, bacteremia, endocarditis, arthritis, osteomyelitis and sepsis.1 
Pathogenicity of S. aureus is attributed to the dominant methicillin- and 
vancomycin-resistant strains which have enabled it to acquire resistance to nearly all 
antibiotics used to treat it. These strains feature capsular polysaccharides which which
surrounds the peptidoglycan cell wall. The thick cell wall protects bacteria from 
phagocytic attack by the human polymorph nuclear leukocytes and adaptive immune 
responses while at the same time propagating S. aureus persistence in the human 
bloodstream.2,3 In addition to the peptidoglycan cell wall, S. aureus colonizes human host 
by secreting proteinaceous surface adhesins such as ClfB (clumping factor B proteins) 
and, IsdA (iron-regulated surface determinant A proteins) as well as wall techoic acid  
that enable adhesion onto the human epithelial cells. Secretion of invasive enzymes such 
as staphylokinase and evasive toxins such as cytolytic toxin plays a key role in allowing 
the pathogen to penetrate human tissues with ease while constantly replicating itself.4, 5
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Staphylococcus aureus mechanism of antibiotic resistance 
Methicillin-resistant Staphylococcus aureus (MRSA) is at present the most 
commonly identified antibiotic-resistant pathogen. Methicillin resistance does not mean 
that no drugs will work. It does mean that vancomycin is the only drug which will in 
most instances work against multidrug-resistant staphylococci. The above underlying 
statement could soon be rejected based on the emergence of vancomycin-resistant strains 
that have been observed in some individuals from the previous findings.6
Resistance to beta-lactams 
Resistance to β-lactam antibiotics (e.g. methicillin and penicillin, Figure 1) is due 
to the production of an altered penicillin-binding-protein, known as PBP 2a by the mecA
gene. PBP 2a as a membrane-bound enzyme catalyzes the transpeptidation reaction that 
is required for the cross-linking of peptidoglycan bonds. In addition, the reduced affinity 
of PBP 2a to β-lactam antibiotics has been shown to facilitate survival of the pathogen 
under high concentration of these antibiotics. Most strains of S. aureus also produce a 
class of enzymes known as β-lactamases which can hydrolyze β-lactam antibiotic 
molecules by splitting the amide closed-ring bonds, thus inactivating the drug and 
rendering it inactive. It is believed that synthesis of β-lactamases is influenced by the 
sequential binding of the anti-repressor and the repressor protein that regulates blaZ gene 
that encodes β-lactamase. 7, 8, 9
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Figure 1: β-Lactam antibiotic derivatives.
Resistance to Glycopeptides 
Glycopeptides are a group of drugs with high activity against Gram-positive 
micro-organisms resistant to methicillin. The bactericidal activity is limited to Gram-
positive bacteria because the external membrane of Gram-negative bacteria is not 
permeable to these compounds, due to their hydrophobic characteristic. The mechanism 
of action of glycopeptides involves the inhibition of synthesis and assembly of the cell
wall peptidoglycan polymers. The glycopeptides that historically have been used over the 
years are vancomycin (Figure 2) and teicoplanin. However, several recent reports have 
highlighted the limitations of vancomycin and teichoplanin, and their role in the 
management of serious infections.10, 11 
Teicoplanin, formerly known as teichomycin A, is a lipoglycopeptide with a 
structural similarity to vancomycin and with high bactericidal activity against aerobic and 
anaerobic Gram-positive bacteria. Teicoplanin is involved in the inhibition of 
peptidoglycan formation.  Recent findings have shown that Gram-negative strains are 
more resistant to this agent because it cannot penetrate their lipid membrane. Studies 
have also demonstrated that teicoplanin is less nephrotoxic compared to vancomycin, 
even in the case of close association with aminoglycosides.12
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Prior to development of antibiotics with new modes of mechanism, vancomycin 
became the most widely used control drug for the treatment of body-related infections 
caused by methicillin-resistant Staphylococcus aureus (MRSA). However, its limited 
tissue distribution, as well as the emergence of isolates with reduced susceptibility has led 
to development of alternative therapies that target MRSA.13, 14  
Vancomycin’s mode of action involves inhibition of peptidoglycan cell wall 
synthesis by binding to the D-alanyl-D-alanine terminus of a pentapeptide. The binding 
inhibits addition of late precursors through a transglycosylation process by the 
transglycosylase enzyme thereby preventing peptidoglycan elongation and cross-linking. 
15 It has also been observed that vancomycin appears to have specific activity on RNA 
synthesis and on the permeability of the cytoplasmic membrane in S. aureus. However,
this mode of action is faced by non-specific binding to glycopeptides that occurs within 
the already mature peptidoglycan.  The non-specific binding affects the action of 
autolysins involved in the physiological hydrolysis of peptidoglycan. 16
Figure 2: Vancomycin as a glycopeptide antibiotic. 
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Resistance to Macrolides 
Macrolides are antibiotic agents with a lactone ring made up of twelve or more 
elements. Such compounds portray better tissue penetration and good antimicrobial 
activity against Gram-positive bacteria. Their main mechanism of action is based upon 
protein synthesis inhibition by binding to the 50S ribosomal sub-unit. Their role in 
treatment of MRSA infections is quite limited since they retain efficacy only against a 
small proportion of MRSA strains.17
Resistance to Quinolones 
Quinolones are a heterogeneous group of potent synthetic bactericidal antibiotics. 
Originally derived from nalidixic acid (Figure 3), modern quinolones have evolved to 
compounds with improved activity preferentially against Gram-negative bacteria
(ciprofloxacin, Figure 3, and ofloxacin) or against Gram-positive bacteria (levofloxacin, 
Figure 3, gatifloxacin and moxifloxacin). The best known mechanism is the rapid 
inhibition of bacterial DNA synthesis and replication, by binding to the DNA-gyrase or 
topoisomerase IV.18
Levofloxacin and newer compounds such as gatifloxacin and moxifloxacin have 
markedly improved activity against Gram-positive pathogens. Despite this observation, 
the use of these agents for the treatment of MRSA is still under intense debate. Moreover,
fluoroquinolone resistance can emerge rapidly after widespread utilization of these 
molecules. The selectivity of fluoroquinolones towards MRSA from among 
heterogeneous MRSA has been linked to the increased risk of hospital acquisition of 
MRSA, and not of MSSA (methicillin-sensitive Staphylococcus aureus).19
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Figure 3: Quinolone antibiotic derivatives. 
Resistance to Tetracyclines 
Tetracyclines are bacteriostatic and act by binding to the 30S sub-units. This 
prevents the linking of the aminoacyl-tRNA and the microorganism ribosomes, 
consequently inhibiting protein synthesis. The extended use of tetracyclines in clinical 
practice and emergence of efflux genes and ribosomal protection proteins has led to 
widespread resistance against most Gram-positive and Gram-negative strains. Therefore, 
their role in the treatment of staphylococcal infections is nowadays quite limited.20
Resistance to Trimethoprim/Sulfametoxazole 
Trimethoprim/sulfametoxazole or Co-trimoxazole (Figure 4) belongs to the 
antibiotic group of folate inhibitors that is derived from the fixed combination of 
trimethoprim and sulfamethoxazole. Sulfametoxazole inhibits the production of 
dihydrofolic acid while trimethoprim inhibits the production of tetrahydrofolic acid. 
Dihydrofolic acid and tetrahydrofolic acid are forms of folic acid that S aureus utilizes 
for nucleotides and amino acids synthesis. Trimethoprim inhibits production of 
tetrahydrofolic acid by inhibiting tetrahydrofolate synthase, an enzyme responsible for 
making tetrahydrofolic acid from dihydrofolic acid. By combining both drugs, the two 
important steps required in the synthesis of bacterial proteins are inhibited. Resistance to 
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Co-trimoxazole by MRSA has been linked to the involvement of plasmids that carry 
altered genes. Such genes facilitate amino acid substitution in the Co-trimoxazole drug 
complex rendering it less effective.21
Figure 4: Structure of Co-trimoxazole. 
Development of new anti-microbial drugs for the treatment of Methicillin-Resistant 
Staphylococcus aureus infections 
Generation of new antibiotic drugs has significantly decreased in the past 10 to 15 
years and this can be attributed to the following two major reasons. Firstly, there is the 
constant evolution of new defense mechanisms by MRSA and VRSA that to a larger 
extent results from the over usage and inappropriate dosage of antibiotics. Secondly, 
many challenges met in developing new antibiotic agents with new mechanisms of action 
have led to the pull out of many funding agencies. However, the continuous vigorous 
search for new agents by scientists has paved the way for the emergence of the following 
twenty first century anti-infective drugs proven by FDA for the treatment of MRSA 
based on controlled clinical trials.22  
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Oxazolidinones 
Oxazolidinones are a new class of synthetic antibacterial agents, which have a 
new mechanism of action that involves early inhibition of bacterial protein synthesis. 
Linezolid and tedizolid (Figure 5) are the first molecules of the class of the 
oxazolidinones, and exert their bacteriostatic action by binding to the 50S ribosome, thus 
inhibiting it from complexing with the 30S sub-units, mRNA, tRNA and initiation 
factors. The overall goal is to disrupt the assembly of functional initiation complex of 
protein synthesis hence preventing translation of the mRNA.23 In most instances; other 
protein synthesis inhibitors are only involved in disruption of peptide elongation while 
allowing for the translation of mRNA to take place at the initial stages.
With the new mode of action, oxazolidinone derivatives have been considered 
effective in preventing the synthesis of both staphylococcal and streptococcal virulence 
factors. Secondly, these agents have specific targets that do not coincide with those of 
existing protein synthesis inhibitors hence their activity is maintained irrespective of 
resistance to the other drugs. Thirdly, their activity is unaffected by the rRNA methyl-
ases that modify the 23S rRNA.24
Figure 5: Oxazolidinone antibiotic derivatives. 
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Daptomycin and Telavancin 
Daptomycin is a cyclic lipopeptide and its mode of action against Gram-positive 
bacteria involves insertion of its lipophilic tail into the bacterial cell membrane. This 
results in rapid depolarization of the bacteria cell membrane and potassium ion efflux that 
eventually inhibits protein synthesis, DNA, and RNA. Such actions finally lead to 
bacterial cell lysis.25As a lipoglycopeptide antibiotic agent, telavancin is considered a 
derivative of vancomycin with a hydrophobic side chain attached to the vancosamine 
sugar. Studies have shown that telavancin activity is caused by the combined action on 
the cell wall synthesis and disruption of bacterial cell membrane. Furthermore, it has also 
been demonstrated that telavancin’s role in inhibiting cell wall synthesis resembles that of 
vancomycin whereby the glycopeptide core binds to the terminal acyl-D-alanyl-D-alanine 
chains of the cell wall through hydrogen bonding and hydrophobic packing interaction.
Such interactions prevent peptide chain elongation and cross-linking of the cell wall 
precursors. 26
Quinupristin-Dalfopristin 
Quinupristin/dalfopristin is the first streptogramin that has been licensed for 
antibiotic therapy. This drug is available as a fixed combination of the two compounds 
quinupristin and dalfopristin, with appropriate ratios and has a wide range of activity 
against Gram-positive bacteria including inhibition of mRNA translation. In order to 
carry out its antibacterial activity, the action of both dalfopristin and quinupristin must be 
involved. That is, dalfopristin inhibits protein synthesis and peptide chain elongation by 
binding to the 50S sub-units during the initial stages while quinupristin binds to the 50S
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ribosome subunits at the later stages thereby preventing peptide elongation and release of 
incomplete chains.27
Tigecycline 
As a glycylcycline derivative, tigecycline is made up of minocycline with an N-
alkyl-glycylamido group substituted at the 9 position. These structural properties define 
its broad spectrum of activity and protection from resistance. As a protein synthesis 
inhibitor, tigecycline binds to the 30S ribosomal subunit of bacteria and blocks the entry 
of amino-acyl transfer RNA into the A site of the ribosome. Studies have also indicated 
that steric hindrance due to a large substituent at position 9 enhances the drug activity. 28
Ceftobiprole and Ceftaroline 
An increase in prescription of cephalosporin derivatives against MRSA has been 
attributed to their wide spectrum activity and acceptable levels of safety profile. Studies 
have shown that ceftobiprole’s strong affinity for the PBP 2a results in the formation of a 
stable inhibitory acyl-enzyme complex that retards protein synthesis. This drug is 
currently under phase III clinical trials in the USA though it has been approved in some 
parts of the world.  Ceftaroline as an antimicrobial agent is derived from the modification 
of the fourth-generation cephalosporin cefozopran structure. Both in vivo and in vitro
assessments have shown that ceftaroline possesses a wide spectrum of activity against 
Gram-positive MRSA and its mechanism of action also involves binding to the penicillin-
binding protein (PBP). The effective binding disrupts the mRNA translation and peptide 
chain elongation.29, 30
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Structure of Capsular Polysaccharide of Staphylococcus aureus 
S. aureus produces many components that affect its virulence, including 
extracellular capsular polysaccharides (CPs) which enhance resistance against phagocytic 
uptake by human polymorphonuclear leukocytes. Capsular polysaccharides are polymeric 
carbohydrates attached to the outer surface of S. aureus and have been categorized into 
12 serotypes. However, type 5 and 8 comprise the majority of clinical isolates, and 
thereby represent an important target for the development of a conjugate vaccine. Type 5 
and 8 capsular polysaccharides (Figure 6) are structurally very similar to each other 
(each polysaccharide contains repeating units of D-FucNAc, L-FucNAc, and D-
MaNAcA), but differ only in the linkages between the sugars and in the sites of O-
acetylation.31
 
Type 5: →4)-E-D-ManNAcA-(1→4)-D-L-FucNAc(3OAc)-(1→3)-E-D-FucNAc-(1→
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Type 8: →3)-E-D-ManNAcA(4OAc)-(1→3)-D-L-FucNAc-(1→3)-D-D-FucNAc-(1→
Figure 6: Capsular polysaccharides of serotypes 5 and 8. 
Biosynthesis of UDP-L-FucNAc in S. aureus 
CapF is an essential enzyme for the synthesis of UDP-L-FucNAc (UDP-N-acetyl-
L-fucosamine), a monosaccharide derivative that is a component of CP5 and CP8. The 
pathway for the synthesis of UDP-L-FucNAc from UDP-D-GlcNAc (UDP-2-acetamido-
2,6-dideoxy-D-galactose) has been characterized extensively. This pathway (Figure 7)
involves three enzymes: CapE, CapF and CapG (Figure7). As a bifunctional enzyme, 
CapE catalyzes C-4, C-6 dehydration and C-5 epimerization of UDP-D-GlcNAc. CapF
catalyzes the C-3 epimerization and C-4 reduction of UDP-2-acetamido-2,6-dideoxy-L-
xylo-4-hexulose to UDP-2-acetoamido-2,6-dideoxy-L-talose, which is the second reaction 
in the pathway. UDP-2-acetoamido-2,6-dideoxy-L-talose is epimerized at C-2 by CapG
to give UDP-L-FucNAc which is incorporated into the capsule polysaccharide by 
glycosyl transferase through condensation.32
 
 
13 
 
Figure 7: Biosynthesis of UDP-L-FucNAc in S. aureus. 
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Azide-Phosphine Chemistry 
The azide functionality serves as a reactive functional group both as an 
electrophile and nucleophile. Its wide application in biological systems in peptide 
synthesis is attributed to its unique characteristics such as absence in all naturally 
occurring compounds (i.e. it is bioorthogonal), it participates in chemoselective reactions 
with  a limited number of other functional groups and it’s smaller size that allows it to be 
introduced in biological systems without much alteration. Chemoselective reaction 
between an azide and a phosphine has greatly been utilized in tagging of molecules in 
biological systems.33  
There are many well-documented reactions of azides to afford amides, for 
example the Huisgen 1,3 dipolar cycloadditions and the related click chemistry. The most 
noticeable reaction is the metal-catalyzed reduction of the glycosyl azide to the 
corresponding amine followed by subsequent acylation to yield the glycosyl amide. This 
method suffers from poor anomeric control and potential hydrolysis of the anomeric 
amine. Many of the so called Staudinger-type methods have also generated oxide by-
products which in most cases are very hard to separate.34
 The Staudinger ligation is a well-known technique for synthesizing a variety of 
glycosyl amides, including complex glycopeptides, from a reaction between an azide and 
phosphine. This reaction results in an iminophosphorane which in the presence of water 
hydrolyzes spontaneously into a primary amine and the corresponding phosphine oxide. 
The intermediate can also react with an acylating agent to form an amide product with 
controlled stereochemistry and the by-product is easily removed during the work up.35
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We intend to utilize such properties of this particular reaction in constructing L-FucNAc 
analogues.
Scheme1 shows the accepted mechanism of the Staudinger reaction in which a 
nucleophilic addition of the phosphine at the terminal nitrogen of the azide forms a 
phosphoazide, which in turn loses di-nitrogen (N2) via the 4-membered-ring transition 
state to generate an iminophosphorane, which undergoes hydrolysis in the presence of 
water to form an amine or reacts with an acyl chloride to form an amide compound and 
phosphine oxide.36
 
Scheme 1: Staudinger ligation reaction between an azide and phosphine. 
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Statement of the Problem 
Staphylococcus aureus is a leading cause of nocosomial infections in hospitals 
worldwide and it has become increasingly difficult to treat due to its prevalent resistance 
to antibiotics. Sereotypes 5 and 8 of Staphylococcus aureus are the most virulent strains 
of bacteria in the staphylococcal species due to the formation of polysaccharide capsules, 
which serve as a protective barrier in preventing phagocytosis, thereby enabling these 
invasive pathogens to exist in the bloodstream multiplying and destroying host cells.  
MRSA has wider economic effects that involve indirect costs to the patient and to 
society. In addition, there is some evidence suggesting that MRSA infections increase 
morbidity and the risk of mortality. 
We intend to utilize Staudinger ligation chemistry to construct novel mimics of 
UDP-N-acetyl-L-fucosamine as potential inhibitors for bacterial glycosyltransfares. 
Ongoing efforts also involve attempts at incorporation of oxazolidinone structures into 
the L-fucosamine structure and if successful we hope to carry out bioassay studies on the 
target bacteria.
 
 
17 
 
Results and Discussions 
1.0 Retrosynthetic analysis 
S. aureus produces capsular polysaccharides which enhance resistance against 
phagocytic uptake by human polymorphonuclear leukocytes. L-FucNAc is considered to 
be part of the capsular polysaccharide. The objective of this project was to develop 
synthetic monosaccharide analogues of this structure by introducing different substituents 
at C-2 and C-1 of the fucose unit using both known and new synthetic methods. 
1.1 Synthesis of 1-bromo-2,3,4-tri-O-acetyl-α-L-fucose (3) 
 
 
Scheme 2: Synthesis of 2,3,4-tri-O-acetyl-α-L-fucosyl bromide (3) from L-fucose (1). 
Synthesis of fucosyl bromide 3 (Scheme 2) involved a two-step process from L-
fucose (1) as the main precursor. The commercially available L-fucose was dissolved in 
pyridine and cooled to 0 oC followed by a dropwise addition of acetic anhydride. The 
reaction was stirred overnight and its completion monitored by TLC (1:1, hexane: ethyl 
acetate) which confirmed the formation of compound 2 with the product Rf value of 0.38. 
Analysis of the 1H NMR spectrum of compound 2 revealed that the resonance observed 
as a doublet at 6.34 ppm, with a coupling constant of 2.72 Hz, corresponded to the alpha 
anomeric proton, while the distinct doublet observed upfield at 5.69 ppm, with a coupling 
constant of 8.28 Hz corresponded to the beta anomeric proton. Integration of the ratios 
(α:β, 10:1) confirmed that compound 2 had an alpha configuration formed in large 
amounts. Analysis of the 13C NMR showed 4 distinct peaks at 169.09-170.49 ppm which 
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corresponded to the carbonyl groups of the acetate protecting groups while the peak at 
92.96 ppm corresponded to the anomeric carbon.
Fucosyl bromide 3 was synthesized via treatment of compound 2 with 33% 
hydrobromic acid (HBr) in glacial acetic acid (AcOH) that resulted in the substitution of 
the anomeric acetate with bromide through an SN1 reaction mechanism. Analysis of the 
1H NMR spectrum of compound 3 revealed that the resonance observed as a doublet at 
6.70 ppm with a coupling constant of 3.92 Hz, corresponded to the anomeric proton 
confirming that compound 3 had an alpha configuration. 
The alpha configuration of bromide 3 is considered to arise from the fact that the 
electronegative group at the anomeric position was thermodynamically favored in the 
axial orientation alignment which allowed for an overlap of the anti-bonding orbital with 
the lone pair of electrons on the oxygen ring. Using the Karplus model curve, the 
previous works34 showed that the dihedral angle between H1 and H2 is 60o as illustrated 
in the Newman projection of compound 3 (Figure 8).  
Figure 8: Dihedral angle between H1 and H2 of compound 3.
The 13C NMR spectrum of bromide 2 confirmed loss of one of the acetyl 
protecting groups as there were only 3 signals observed at 169.79-170.25 ppm while the 
peak at 89.32 ppm corresponded to the anomeric carbon. 
 
 
19 
 
1.2 Synthesis of 1,3,4-tri-O-acetyl-2-azidodeoxy-α,β-L-fucose (6) 
Scheme 3: Synthesis of 1,3,4-tri-O-acetyl-2-azidodeoxy-α,β-L-fucose (6). 
Glycals (e.g. 4, Scheme 3) are well known synthesis intermediates for the 
preparation of oligosaccharides, O- or C-glycosides and non-carbohydrate-based natural 
products. They can be easily transformed into 2-amino-2-deoxy sugars which are not 
easily obtained by other means. Schwartz and coworkers reported on a mild and efficient 
means for reduction of glycosyl bromides using the dimeric titanium (III) reagent in.37
THF promotes a fast electron transfer to the bromide to give an anomeric radical species 
which is reduced by another Cp2TiCl to give glycosyl titanium(IV) complex which then 
eliminates Cp2TiCl(OAc) (Scheme 4).
Scheme 4: Mechanism for the reduction of fucosyl bromide to fucal with (Cp2TiCl)2. 
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Compound 4 was synthesized by dissolving (Cp2TiCl)2 and Mn in THF followed 
by addition of a catalytic amount of TMSCl. Fucosyl bromide 3 in THF was then added 
in a dropwise fashion to the mixture and reaction mixture was vigorously stirred 
overnight. Completion of reaction was confirmed by TLC (3:1, hexane: ethyl acetate) 
with a product Rf value 0.30 which was lower than that of compound 3. Analysis of the 
1H NMR spectrum of compound 4 revealed that the resonance observed as a doublet of 
doublets at 6.46 ppm with coupling constants of 1.88 Hz and 6.34 Hz, corresponded to 
the two vinyl hydrogens. Analysis of the 13C NMR spectrum showed two distinct peaks 
at 170.39 and 170.68 ppm which corresponded to the carbonyl groups of the acetate 
protecting groups, an indication of loss of one acetate protecting group. 
1.3 Azidonitration of glycals 
The presence of 2-aminosugars in nearly every class of glycoconjugates and a 
number of natural products has inspired the development of synthetic methods for the 
construction of 2-aminoglycosides. The use of glycals as precursors for the synthesis of 
2-amino sugars was pioneered by Lemieux, who introduced the azidonitration process, 
where glycals are transformed to 2-aminopyranosyl derivatives.38In a typical example, 
treatment of fucal 4 with CAN and sodium azide in acetonitrile gave 2-azido-
deoxyfucose 5 which was further functionalised to provide fucosyl acetate 6.
Though the mechanism of the azidonitration is not still clear, studies done by 
Trahanovsky et a1on oxidation of organic compounds with cerium(IV) to form azido-
nitrate-alkanes from olefins, showed  that the regioselectivity of the reaction presumably 
involves addition of an azide radical to form a radical intermediate containing the azide 
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group. The azide radical can be generated according to the reaction shown in equation 
(1). The azide radical is then trapped by the olefins in preference to forming nitrogen gas. 
 
Equation 1: Generation of azide radical. 
The overall reaction then proceeds as shown in Scheme 5 where the resulting 
anomeric radical 2-azido-deoxyfucosyl is oxidized by cerium (IV) to form the 
oxocarbenium ion which can then react with the nucleophilic nitrate ion on either face 
depending probably on the orientation of the C-2 azide and the anomeric effect.39 
Scheme 5: Proposed mechanism for azidonitration reaction. 
In order to prepare compound 5 a mixture of sodium azide and ceric ammonium 
nitrate was cooled to -15 oC in an acetone dry-ice bath. A pre-cooled solution of L-fucal 4
in anhydrous acetonitrile was then added slowly into the reaction flask and the resulting 
mixture was stirred vigorously at -15 oC for 5 hours under inert conditions. Completion 
of reaction was confirmed by TLC (3:1 pet. ether: ethyl acetate) with the product Rf value 
of 0.36. The resulting product was used in the next step without further purification. 
Analysis by the 1H NMR spectrum confirmed the formation of compound 5 whereby the 
peak observed downfield at 6.31 ppm (d, J = 4.16 Hz) was identified as proton adjacent 
to the nitrate group (CH-NO2). Further analysis showed that the peak observed upfield at 
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4.08 ppm (dd, J = 4.18 Hz, 11.30 Hz) corresponded to the proton adjacent to the azide 
group (CH-N3). The 
13C NMR spectrum revealed two peaks at 169.46 and 170.04 ppm 
which corresponded to the carbonyl of acetate group while the peak at 97.86 ppm was 
identified to belong to the C-NO2 carbon and 55.89 ppm corresponded to the C-N3
carbon. The IR spectrum showed strong band peaks at 2114.58 cm-1 and 1686.05 cm-1
confirming that azide and nitrate groups were present in the sugar compound. 
1.4 Azidochlorination of Glycals 
Protected glycals have a long history of use as building blocks in carbohydrate 
chemistry, particularly because of their effectiveness as glycosyl donors. 
Azidochlorination as a method for preparation of 2-amino sugars involves treatment of 
protected glycals with ferric chloride, sodium azide, and catalytic amount of hydrogen 
peroxide in acetonitrile to yield 2-azido galactosyl chlorides. These compounds are good 
intermediates for synthesis of 2-N-acetamido-2-deoxygalactosides that are components of 
naturally occurring glycoconjugates and oligosaccharides.40
However, this particular reaction resulted in lower yield for compound 19
(Equation 2) and only traces for compound 20 (Equation 3) which could not be purified 
through column chromatography for the next reaction step.  
 
 
Equation 2: Synthesis of 3,4,6-tri-O-acetyl-2-azidodeoxy-1-chloro-α,β-D-glucose (19). 
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Equation 3: Attempted synthesis of 3,4-di-O-acetyl-2-azidodeoxy-1-chloro-α,β-L-fucose 
(20). 
Compound 19 was prepared by cooling a mixture of compound 18, sodium azide,
and iron (III) chloride in dry acetonitrile at -30 oC followed by dropwise addition of 
hydrogen peroxide resulting in 5% yield (Equation 2). The 1H NMR spectrum of 
compound 19 revealed a peak downfield at 6.35 ppm (d, J = 5.92 Hz). The downfield 
shift of C-Cl was due to the deshielding effect of chloride as a good electron-withdrawing 
group. A peak observed upfield at 3.62 ppm (dd, J = 3.76, 10.56 Hz) further confirmed 
that azide was coupled onto the C-2 carbon. Characterization by the 13C NMR spectrum 
revealed three peaks at 169.67-170.68 ppm which corresponded to the carbonyls of 
acetate groups while the peak at 96.50 ppm was identified to belong to the C-Cl carbon 
and 53.38 ppm corresponded to the C-N3 carbon. 
1.5 Conversion of azido nitrates to azido acetates 
Preparation of compound 6 involved treatment of compound 5 with acetic acid, 
sodium acetate, and a catalytic amount of acetic anhydride. The mixture was refluxed for 
5 hours and completion of reaction confirmed by TLC (6:4, hexane: ethyl acetate). The 
proton NMR spectrum confirmed that the product consisted of two anomers  and was 
used for the next step without isolation of the two products. Analysis of the 1H NMR 
spectrum of compound 6 revealed that the resonance observed downfield at 6.29 ppm (d, 
J = 3.64 Hz) corresponded to the β-anomeric proton while the upfield peak at 5.53 ppm 
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(d, J = 8.48 Hz), corresponded to the α-anomeric proton. The substitution of the nitrate 
group with the acyl group was further confirmed by the 13C NMR spectrum from the 
three peaks observed at 169.65-170.29 ppm, and at 20.59-20.96 ppm. These peaks 
corresponded to the carbonyl and methyl groups on the acetates respectively. 
1.6 Synthesis of amides from azides via non-traceless Staudinger reaction 
N-Glycosyl amide functionality has been utilized in the synthesis of various 
carbohydrate derivatives as well as their utilization in glycosylation reactions. Therefore, 
an extensive exploration into simple and safe methodologies for their synthesis has been 
given much attention in the recent past.  
The Staudinger reaction as a tool of chemo-selective conjugation has been utilized 
to form stable amide bonds by trapping a nucleophilic intermediate formed from the 
reaction of a phosphine and an azide using acyl chloride (Scheme 6). Utilization of DPPE 
in the Staudinger reactions generates a phosphine oxide by-product that is readily 
removed allowing for rapid and simple purification of the reaction mixture. 
 
Scheme 6: Modified non-traceless Staudinger reaction. 
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Table1. Synthesis of L-FucNAc derivatives from acyl chlorides 
  
Starting material Acyl chloride Product Yield 
(%)
6 Phenyl acetyl chloride 7 51
Benzyl chloroformate 8 30
13 Benzyl chloroformate 9 28
6 4-methoxy benzoyl chloride 10 47
4-chloro benzoyl chloride 11 54
2-chloro benzoyl chloride 12 50
15 4-methoxybenzoyl chloride 13 57
Table2. Structures of L-FucNAc Synthons 
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Equation 4: Synthesis of 1,3,4-tri-O-acetyl-2-N-(phenylacetamido)-α,β-L-fucose (7).
Amide 7 was obtained from a one-step synthetic protocol with 51% overall yield 
(Equation 4). In more details, azide 6 was treated with phenyl acetyl chloride and DPPE 
(1,2-bis (diphenylphosphine )ethane) in THF and the formation of amide 7 confirmed by 
TLC (2:1, hexane:ethyl acetate) with the product  Rf value of 0.36. Characterization by 
the proton NMR indicated little to no anomerization at the anomeric position with azide 6
having coupling constant of 3.64 Hz while the amide 7 had a coupling constant of 4.16 
Hz. Further analysis of the proton spectrum revealed a peak downfield at 8.04 ppm (d, J 
= 8.20 Hz). This peak was assigned to the proton adjacent to the nitrogen, and the 
multiplicity of doublets of doublets indicated that the proton was coupled to two protons 
with different electronic environments. The observed downfield shift was attributed to the 
deshielding effect of the amide nitrogen. The 13C NMR spectrum revealed three peaks at 
169.50-170.08 ppm which corresponded to the carbonyls of acetate groups while the peak 
at 55.93 ppm was identified to belong to the C2-N carbon and 159.63 ppm corresponded 
to the amide carbonyl.  The IR spectrum showed strong bands at 1640.90 cm-1, 1755.44 
cm-1, and 3156.06 cm-1 which were assigned to the amide carbonyl, acetate carbonyl and 
NH respectively. 
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Equation 5: Synthesis of 1,3,4-tri-O-acetyl-2-N-(benzyloxyacetamido)-α,β-L-fucose (8).
Staudinger reaction protocol was utilized in the reduction of azide 6 eventually 
resulting in the formation of compound 8 in 30% yield (Equation 5). A reaction between 
an azide and benzyl ester in the presence of a reducing agent has extensively been 
utilized in formation of the key intermediate in this case; amide 8 which undergoes  
addition reactions to generate oxazolidinone derivative (Scheme 7).
Scheme 7: Schematic representation of Oxazolidinone derivative synthesis from 8.
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Analysis by the proton NMR confirmed the formation of compound 8 whereby 
the distinct peak observed at 5.69 ppm (d, J = 2.36 Hz) was assigned the anomeric proton 
while the peak observed further downfield at 6.34 ppm (d, J = 8.28 Hz) was assigned to 
the proton adjacent to the nitrogen. Further characterization by the 13C NMR spectrum 
revealed three peaks at 169.94-170.57 ppm which were assigned to the carbonyls of 
acetate groups while the peak at 55.69 ppm was identified to belong to the carbon 
adjacent to the nitrogen. In addition to that, the peak at 46.36 ppm was assigned the 
(CH2) carbon and a significant peak at 156.72 ppm confirmed the reduction of an azide to 
an amide. The IR spectrum also proved that the reduction process had taken place as was 
shown by the shift of the azide band from 2114.58 cm-1 to amide carbonyl band at 
1649.76 cm-1. Other significant band was at 1746.66 cm-1 and it was assigned to the 
acetate carbonyls. 
Our main goal was to transform compound 8 into intermediate II (Scheme 7)
which would then undergo nucleophilic additions to generate Oxazolidinone derivative as 
a potential antibacterial drug with new mechanism of action. However, treatment of 
compound 6 with benzyl chloroformate and DPPE in THF resulted in formation of 
compound 8 and compound 14 (Figure 9). Formation of 14 in larger amounts compared 
to 8 affected our next synthetic step because the amount of starting material was of great 
importance in this case. The 1H NMR spectrum of compound 14 showed a peak at 3.65 
ppm (d, 2H, J = 13.76Hz) indicating a methylene group coupled to the phosphorous. 13C 
NMR revealed a peak at 38.18 ppm (d, C-P, J = 66.55 Hz) confirming the methylene 
carbon was coupled to the phosphorous and 31P NMR also showed a peak at 29.31 ppm. 
 
 
29 
 
We noted that addition of benzyl chloroformate prior or after the formation of 
aza-ylide (Scheme1) still led to the formation of compound 14, therefore, mechanistic 
aspects of the reaction outcome are yet to be fully understood.
 
Figure 9: Compound formed in the presence of DPPE and benzyl chloroformate. 
 
Equation 6: Synthesis of 1,3,4,6-tetra-O-acetyl-2-N-(benzyloxyacetamido)-α,β-L-
glucose (9).
The protocol utilized in synthesis of compound 9 was similar to that of compound 
8 resulting in 28% yield (Equation 6). Characterization by the 1H NMR spectrum on 
compound 9 showed a peak at 5.65 ppm (d, J = 2.31 Hz) which was assigned to the 
anomeric proton. Observance of a peak at 6.43 ppm (d, J = 8.03 Hz) further affirmed the 
presence of a proton adjacent to the nitrogen in the compound. The 13C NMR spectrum 
revealed four peaks at 168.49-170.51 ppm that indicated the presence of carbonyls of 
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acetate groups while the peak at 55.61 ppm was identified to belong to the sugar carbon 
attached to the nitrogen. The presence of methylene group was affirmed by the peak at 
46.23 ppm and a significant peak at 156.58 ppm confirmed formation of an amide 
compound. The IR spectrum showed strong bands at 1647.73 cm-1, 1751.56 cm-1, and 
3156.37 cm-1 which were assigned to the amide carbonyl, acetate carbonyl, and NH, 
respectively. 
Equation 7: Synthesis of 1,3,4-tri-O-acetyl-2-N-(4-methoxybenzamido)-α,β-L-fucose 
(10).
Compound 10 was synthesized from a reaction of azide 6 with 4-methoxybenzoyl 
chloride resulting in 47% yield (Equation 7) and completion of reaction confirmed by 
TLC (2:1, hexane:ethyl acetate) with an Rf  value of 0.29 for the product. The 
1H NMR 
spectrum showed a peak at 6.31 ppm (d, J = 3.44 Hz) which was assigned as the 
anomeric proton and the smaller differences noted in coupling constants for the anomeric 
proton of 6 and 10 indicated little anomerization at the anomeric position. A downfield 
peak at 8.09 ppm (d, J = 8.11 Hz) corresponded to the nitrogen proton and the 
multiplicity of doublet of doublets was an indication that the proton was coupled to two 
protons in different environments. The presence of the methoxy protons was also 
affirmed by the signal observed upfield at 3.87 ppm (s, 3H) and the multiplicity observed 
as a singlet in this case showed that the three protons were not coupled to any proton.  
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Presence of carbonyls of acetate protecting groups was confirmed by the 13C NMR 
spectrum by the three peaks observed at 168.51-170.57 ppm while the peak at 55.65 ppm 
resulted from the attachment of the nitrogen to the second carbon of the sugar derivative. 
The peak at 158.99 ppm confirmed the presence of amide carbonyl. IR spectrum was 
utilized to further confirm the reduction of an azide to amide as was shown by the band 
peak at 1605.31 cm-1 which corresponded to the amide carbonyl. The band at 1755.44 
cm-1 was assigned to the acetate carbonyl groups. 
 
Equation 8: Synthesis of 1,3,4-tri-O-acetyl-2-N-(4-chlorobenzamido)-α,β-L-fucose (11).
 In order to prepare compound 11, azide 6 was treated with two equivalence of 4-
chlorobenzoyl chloride resulting in 54% yield (Equation 8). Formation of 11 was 
confirmed by the 1H NMR spectrum whereby the peak observed at 6.47 ppm (d, 1H, H-1, 
J = 4.84 Hz) was assigned to the anomeric proton. A significant shift of the azide peak 
(3.81 ppm) to an amide peak at 8.03 ppm (d, J = 8.60 Hz) confirmed the reduction of the 
azide to amide.  The 13C NMR spectrum revealed three peaks at 169.92-170.62 ppm 
which corresponded to the carbonyls of acetate groups while the distinct peak at 160.20 
ppm corresponded to the amide carbonyl. IR spectrum showed bands at 1645.13 cm-1, 
1747.80 cm-1, and 3156.01 cm-1 which were assigned to the amide carbonyl, acetate 
carbonyls, and NH, respectively. 
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Equation 9: Synthesis of 1,3,4-tri-O-acetyl-2-N-(2-chlorobenzamido)-α,β-L-fucose (12).
Nucleophilic addition of the phosphine (DPPE) at the terminal nitrogen of the 
azide 6 in the presence of 2-chlorobenzoyl chloride led to the formation of compound 12
in 50% yield (Equation 9) with the product  Rf value of 0.30 by TLC (2:1, hexane:ethyl 
acetate). Characterization by 1H NMR spectroscopy revealed a peak at 5.69 ppm (d, J =
2.84 Hz) that was assigned the anomeric proton while the peak observed at 8.02 ppm (d, 
J = 8.80 Hz) was assigned to the nitrogen proton. The larger coupling constant of the 
amide proton compared to the azide coupling constant (4.15 Hz) affirmed that we had 
indeed formed compound 12. Peaks observed between 169.90-170.80 ppm in the 13C
NMR spectrum revealed the presence of carbonyls of acetate groups while the peak at 
60.30 ppm was identified to belong to the C2-N carbon. A significant peak at 160.42 ppm 
confirmed the presence of amide carbonyl in the carbohydrate derivative 12. IR spectrum 
further confirmed the conversion of azide 6 to amide 12 by the strong band peak at 
1651.02 cm-1 that was assigned the amide carbonyl while the band peak at 1747.81 cm-1
was assigned the acetate carbonyls. 
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Equation 10: Synthesis of 1,3,4,6-tetra-O-acetyl-2-N-(4-methoxybenzamido)-α,β-D-
glucose (13). 
Compound 13 was synthesized by employing the Staudinger reaction protocol for 
compound 10 resulting in 57% yield (Equation 10). Appearance of a purple spot with an 
Rf value of 0.37 on TLC plate upon staining and heating on a hot plate was an indication 
of the formation of compound 13. Analysis by the 1H NMR spectrum showed a peak at 
6.34 ppm (d, J = 3.40Hz) which corresponded to the anomeric proton while the peak at 
8.06 ppm (d, J = 8.13 Hz) was assigned the nitrogen proton. The presence of the methoxy 
protons was also affirmed by the signal observed upfield at 3.87 ppm (s, 3H). Further 
analysis done by 13C NMR spectrum revealed four peaks at 168.50-170.54 ppm which 
corresponded to the carbonyls of acetate groups while the peaks at 29.70 ppm and 55.72 
ppm were identified to belong to the methoxy carbon and the C2-N carbon respectively. 
Formation of an amide was proven by the peak at 159.00 ppm that was assigned the 
amide carbonyl. IR spectrum showed strong bands at 1605.31 cm-1, 1755.44 cm-1, and 
3156.62 cm-1 which were assigned to the amide carbonyl, acetate carbonyl, and NH, 
respectively. 
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Equation 11: Attempted synthesis of compounds 16 and 17 from di-substituted acyl 
chlorides. 
Treatment of 6 with either terephthaloyl chloride or isophthaloyl chloride and 
DPPE in THF neither led to the formation of 16 nor 17, respectively (Equation 11). The 
azide orientation or steric effects are thought to have had great influence in the observed 
outcome. It is also suggested that attachment of the azide onto the sugar molecule also 
makes it difficult to have acyl substitution at both sides of the electrophilic carbonyl of 
the two acyl chlorides.  
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Conclusion 
Throughout this project we have succeeded in synthesizing various L-FucNAc 
analogs through the utilization of non-traceless modified Staudinger reaction as a 
feasible, safe and efficient method. We hope that optimization of our reaction conditions 
could result in optimum yields which could be tested and evaluated against 
Staphylococcus aureus bacteria. 
The impracticability of azidochlorination method was also demonstrated, 
establishing that this approach was not a feasible route to 3,4-di-O-acetyl-2-azido-
deoxyfucose derivative 20 and 3,4,6-tri-O-acetyl-2-azido-2-deoxyglucose derivative 19 
which are good intermediates for synthesis of 2-N-acetomido deoxysugar derivatives that 
are components of naturally occurring glycoconjugates and oligosaccharides.
In the future, we would also want to study the feasibility of converting fucose unit 
6 to an amine derivative to avoid the formation of side product 14 in the presence of 
DPPE and benzyl chloroformate. This will then allow us to easily introduce our 
oxazolidinone structure onto the fucose unit and if successful evaluate their activity 
against Staphylococcus aureus bacteria. 
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GENERAL EXPERIMENTAL PROCEDURES
All reagents used were purchased from commercial sources and used without 
further purification. All reactions were done in oven-dried glassware fitted with rubber 
septum and magnetic stir bar. The reactions were monitored by thin layer 
chromatography whereby the spots made on the TLC plates (Aluminum- backed plates 
coated with silica gel) were detected upon dipping in 5% Sulfuric acid- 95% ethanol 
solution and heating on hot plate. A Bruker Avance III 400 NMR system was used to 
obtain 1H, 13C and COSY spectrum at frequencies of 400 MHz and 100 MHz using 
CDCl3 as solvent. Chemical shifts were measured in parts per million (ppm) and the 
coupling constants measured in Hertz (Hz). 
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1,2,3,4-Tetra-O-acetyl-α,β-L-fucose (2). L-Fucose (5.0 g, 30 mmol) was dissolved in 
pyridine (20 mL, 248 mmol) under nitrogen atmosphere and the mixture cooled in an ice-
water bath at 0 oC. Acetic anhydride (50 mL, 529 mmol ) was then added dropwise  and 
the reaction allowed to stir  for 4 hrs during which the target product showed an Rf  value 
of 0.38 by TLC (1:1, hexane-ethyl acetate) confirming completion of the reaction. The 
crude mixture was then transferred to a 250 mL Erlenmeyer flask containing 40 mL ice-
water and was gently stirred till all the ice melted. Organic product was extracted with 
methylene chloride (30 mL) and washed with 5% H2SO4 (3 × 20 mL) followed by DI
H2O (2 × 50 mL). The Organic layer was dried over anhydrous magnesium sulfate. 
Evaporation in vacuo afforded compound 2 as a colorless syrup (8.5 g, 28 mmol, 
93.33%).  
α – Anomer 
1H NMR (CDCl3) δ 1.16 (d, 3H, J = 6.52 Hz), 2.00, 2.01, 2.14, 2.18  (s, 12H), 
4.12 (dq, 1H,  H-5, J = 7.13 Hz), 4.27 (dd, 1H, H-4, J = 6.42, 12.94 Hz), 5.08 (dd, 
1H, H-3, J = 3.48, 10.38 Hz), 5.27 (dd, 1H, H-2, J = 0.87, 3.39 Hz), 6.34 (d, 1H, 
H-1, J = 2.75 Hz ). 
β – Anomer 
1H NMR (CDCl3) δ 1.16 (d, 3H, J = 6.52 Hz), 2.00, 2.01, 2.14, 2.18   (s, 12H), 
4.12 (dq, 1H, H-5, J = 7.13 Hz), 4.27 (dd, 1H, H-4, J = 6.42, 12.94 Hz), 5.08 (dd, 
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1H, H-3, J = 3.48, 10.38 Hz), 5.27 (dd, 1H, H-2, J = 0.87, 3.39 Hz), 5.69 (d, 1H, 
H-1,  J = 8.29 Hz ). 
13C NMR (CDCl3) δ 15.04, 20.53, 20.57, 20.63, 20.88, 66.51, 67.29, 67.85, 70.61, 
90.00, 169.09, 169.90, 170.14, 170.49. 
Rf = 0.38 (1:1 hexane: ethyl acetate).  M.P (
oC) = N/A syrup 
2,3,4-Tri-O-acetyl-1-bromo-α-L-fucose (3). L-fucosyl tetraacetate (2, 8.50 g, 28 mmol) 
was dissolved in 33% HBr in glacial acetic acid (70 mL) and the resulting brown solution 
mixture  allowed to stir for three hours during which the target product showed an Rf
value of 0.39  by TLC (1:1, hexane-ethyl acetate) confirming completion of the reaction. 
The reaction mixture was then diluted with methylene chloride (25 mL), cooled to 0 oC
and thereafter neutralized with 10% aqueous sodium hydroxide (50 mL) and saturated 
sodium hydrogen carbonate (5 mL). The mixture was then extracted with methylene 
chloride (3 × 25 mL), washed with DI H2O (3 × 25 mL), and dried over anhydrous 
magnesium sulfate. Evaporation in vacuo afforded compound 3 as a brown syrup. (7.24 
g, 20.5 mmol, 73 %). 
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1H NMR (CDCl3) δ 1.22 (d, 3H, J = 6.52 Hz), 2.01, 2.11, 2.17 ( s, 9H ), 4.41 (q, 
1H, H-5,  J = 6.54 Hz), 5.03 (dd, 1H, H-4, J = 3.92, 10.56 Hz ), 5.36 (dd, 1H, H-
2, J = 1.24, 3.32 Hz ), 5.40 ( dd, 1H, H-3, J = 3.28, 10.60 Hz), 6.70 (d, 1H, H-1, J
= 3.92 Hz). 
13C NMR (CDCl3) δ 15.57, 20.55, 20.61, 20.77, 67.91, 68.47, 69.86, 70.06, 89.32, 
169.79, 170.13, 170.25. 
Rf = 0.39 (1:1 hexane: ethyl acetate).  M.P (
oC) = N/A syrup 
 
3,4-Di-O-acetyl-L-fucal (4). Cp2TiCl2 (3.62 g, 14.5 mmol), and Mn granules (1.81 g, 
32.9 mmol) were added to THF (15 mL). A catalytic amount of TMSCl (0.51 mL) was 
then added and the mixture allowed to stir for 20 min. A solution of L-fucosyl bromide 3
(7.24 g, 20.5 mmol) in THF (15 mL) was added dropwise into the reaction flask then 
stirred vigorously and the reaction monitored by TLC (3:1 hexane: ethyl acetate). Change 
of color from red to green-blue was an indication of reaction going to completion with 
the product Rf value of 0.30 that was lower than the starting material. The mixture was 
diluted with CH2Cl2 (30 mL) and the inorganic material filtered off through a short 
vaccum column. The filtrate was then concentrated in vacuo to afford a brown syrup 
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which was purified via flash column chromatography (3:1, hexane: ethyl acetate) yielding 
compound 4 as a light green oil. (3.62 g, 16.9 mmol, 82%).  
1H NMR (CDCl3) δ 1.28 (d, 3H, J = 6.64 Hz), 2.02, 2.16 (s, 6H ), 4.22 (dd, 1H, 
H-2,  J = 6.54, 13.21 Hz), 4.64 (dq, 1H, H-5, J = 6.34 Hz ), 5.29 (dd,  1H, H-4, J
= 1.35, 4.62 Hz ), 5.58 (dd, 1H, H-3, J = 1.06, 4.66 Hz), 6.46 (dd, 1H, H-1, J =  
1.88, 6.32 Hz).
13C NMR (CDCl3) δ 16.52, 20.69, 20.85, 65.07, 66.33, 71.55, 98.29, 146.13, 170. 
39, 170.68.
Rf = 0.30 (3:1 hexane: ethyl acetate).  M.P (
oC) = N/A oil 
3,4-Di-O-acetyl-2-azidodeoxy-1-nitro-α,β-L-fucose (5). A mixture of sodium azide 
(1.65 g, 16.6 mmol) and ceric ammonium nitrate (27.80 g, 33.3 mmol) was cooled to -15 
oC in an acetone dry- ice bath. A pre-cooled solution of L-fucal 4 (3.6 g, 16.9 mmol) in 
anhydrous acetonitrile (20 mL) was slowly added into the reaction flask and the resulting 
mixture was stirred vigorously at -15 oC for 5 hrs under inert conditions. Completion of 
reaction was confirmed by TLC (3:1 Pet. Ether: ethyl acetate) with the product Rf value 
of 0.36. The resulting yellow mixture was diluted with CH2Cl2 (30 mL) and washed with 
DI H2O (4 × 20 mL). The Organic layer was dried over anhydrous MgSO4, filtered, and 
evaporated in vacuo to afford compound 5 as a yellow syrup (2.90 g, 9.6 mmol, 57 %). 
 
 
41 
 
α – Anomer 
 
1H NMR (CDCl3) δ 1.18 (d, 3H, J = 6.52 Hz), 2.07, 2.19 (s, 6H ), 4.08 (dd, 1H, 
H-2,  J = 4.18, 11.30 Hz), 4.30 (dq, 1H, H-5, J = 6.48 Hz ), 5.25 (dd, 1H, H-4, J =
3.16, 11.28 Hz ), 5.35 (dd, 1H, H-3, J = 1.20, 3.20 Hz), 6.31 (d, 1H, H-1, J =  4.16 
Hz). 
β – Anomer 
 
1H NMR (CDCl3) δ 1.18 (d, 3H, J = 6.52 Hz), 2.07, 2.19 (s, 6H ), 4.08 (dd, 1H, 
H-2,  J = 4.18, 11.30 Hz), 4.30 (dq, 1H, H-5, J = 6.48 Hz ), 5.25 (dd,  1H, H-4, J
= 3.16, 11.28 Hz ), 5.35 (dd, 1H, H-3, J = 1.20, 3.20 Hz), 5.56 (d, 1H, H-1, J =  
8.84 Hz). 
13C NMR (CDCl3) δ 15.85, 20.50, 20.53, 55.89, 68.08, 68.96, 69.72, 97.86, 
169.46, 170.04. 
IR (CDCl3) 2115.63 cm
-1 (N3), 1751.27 cm
-1 (acetate carbonyls), 1674.28 cm-1
(nitrate). 
Rf = 0.30 (3:1 Pet. Ether: ethyl acetate).  M.P (
oC) = N/A syrup 
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1,3,4-Tri-O-acetyl-2-azidodeoxy-α,β-L-fucose (6). Compound 5 (2.90 g, 9.6 mmol) and 
sodium acetate (3.65 g, 44.5 mmol) were dissolved in glacial acetic acid (85 mL). Acetic 
anhydride (4.5 mL) was then added and the resulting mixture was refluxed for 5 hrs. 
Crude mixture was extracted with CH2Cl2 (25 mL) and transferred into a 250 mL 
Erlenmeyer flask containing ice-water. The Organic layer was washed with NaHCO3 (2 × 
30 mL) followed by 10% NaCl (2 × 20 mL), dried over anhydrous MgSO4, filtered, and 
evaporated in vacuo to afford compound 6 as a light brown syrup. (1.61 g, 5.1 mmol, 
53%).  
α - Anomer 
1H NMR (CDCl3) δ 1.22 (d, 3H, J = 6.44 Hz), 2.18, 2.19, 2.22 (s, 9H ), 3.81 (dd, 
1H, H-2,  J = 8.52, 10.80 Hz), 3.90 (dq, 1H, H-5, J = 6.44 Hz ), 4.89 (dd, 1H, H-
4, J = 3.36, 10.80 Hz ), 5.23 (dd, 1H, H-3, J = 0.90, 3.32 Hz), 6.29 (d, 1H, H-1, J
=  3.64 Hz). 
13C NMR (CDCl3) δ 15.97, 20.67, 20.91, 20.96, 67.25, 69.37, 71.74, 92.96, 
169.65,  169.89, 170.29.
IR (CDCl3) 2114.61 cm
-1 (N3), 1751.27 cm
-1 (acetate carbonyl). 
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β -anomer 
1H NMR (CDCl3) δ 1.22 (d, 3H, J = 6.44 Hz), 2.18, 2.19, 2.22 (s, 9H ), 3.81 (dd, 
1H, H-2,  J = 8.52, 10.80 Hz), 3.90 (dq, 1H, H-5, J = 6.44 Hz ), 4.89 (dd, 1H, H-
4, J = 3.36, 10.80 Hz ), 5.23 (dd, 1H, H-3, J = 0.90, 3.32 Hz), 5.53 (d, 1H, H-1, J
=  8.48 Hz). 
13C NMR (CDCl3) δ 15.97, 20.67, 20.91, 20.96, 67.25, 69.37, 71.74, 92.96, 
169.65, 169.89, 170.29. 
Rf = 0.34 (6:4 hexane: ethyl acetate).  M.P (
oC) = N/A syrup 
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General procedure for conversion of Azides to Amides via modified Staudinger 
reaction 
One equivalent of fucosyl azide and two equivalents of acylating agent were 
dissolved in anhydrous THF (0.1 g/mL). A solution of DPPE (0.65 mmol equiv.) in 
anhydrous THF was added dropwise to the mixture which was allowed to stir for 2 hrs at 
rt under inert conditions. Saturated solution of NaHCO3 was added to the mixture after 
TLC (2:1, hexane: ethyl acetate) showed consumption of aza-ylide intermediate. The 
reaction mixture was then stirred vigorously for 3 hrs after which the organic solvent was 
removed under reduced pressure and the resulting mixture extracted with CH2Cl2 and 
water. Organic layer was dried over anhydrous magnesium sulfate and evaporated in
vacuo to afford a solid mixture which was purified by flash column chromatography 
using appropriate solvent system. 
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1,3,4-Tri-O-acetyl-2-N-(phenylacetamido)-α,β-L-fucose (7). Synthesized from 
compound 6 (98 mg, 0.31 mmol), phenyl acetyl chloride (0.08 mL, 0.62 mmol), and 
DPPE (0.65 mmol equiv) in THF according to the general procedure described above. 
Purification by flash column chromatography (2:1, hexane: ethyl acetate) yielded 
compound 7 as a colorless syrup (65 mg, 0.16 mmol, 51%).
1H NMR (CDCl3) δ 1.22 (d, 3H, J = 6.44 Hz), 2.07, 2.15, 2.19 (s, 9H), 3.49 (s, 
2H),  3.98 (dq, 1H, H-5, J = 6.42 Hz), 4.20 (ddd, 1H, H-2, J = 2.58, 6.22, 12.44 
Hz), 5.08 (dd,  1H, H-4, J = 3.34, 10.94 Hz), 5.24 (dd, 1H, H-3, J = 0.94, 3.34 
Hz), 6.31 (d, 1H, H-1, J = 4.16 Hz), 7.26-7.32 (m aryl group), 8.04 (d, 1H, NH, J
= 8.20 Hz). 
13C NMR (CDCl3) δ 15.89, 20.42, 20.53, 20.56, 29.71, 55.93, 68.11, 69.00, 69.76, 
71.21, 97.48, 125.32, 128.24, 129.05, 159.63, 169.50, 169.50, 170.08.
IR (CDCl3) 3156.47 cm
-1 (NH), 1755.44 cm-1 (acetate carbonyls), 1640.90 cm-1
(NHCO).
Rf = 0.36 (2:1 hexane: ethyl acetate).  M.P (
oC) = N/A syrup 
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1,3,4-Tri-O-acetyl-2-N-(benxyloxyacetamido)-α,β-L-fucose (8). Synthesized from 
compound 6 (100 mg, 0.32 mmol), benzyl chloroformate (0.10 mL, 0.64 mmol), and
DPPE (0.65 mmol equiv) in THF according to the general procedure described above. 
Purification by flash column chromatography (2:1, hexane: ethyl acetate) yielded 
compound 8 as a colorless syrup (40 mg, 0.095 mmol, 30 %). 
1H NMR (CDCl3) δ 1.15 (d, 3H, J = 6.44 Hz), 2.00, 2.02, 2.15 (s, 9H), 3.93 (dq,
1H, H-5, J = 6.40 Hz), 4.12 (ddd, 1H, H-2, J = 2.58, 5.56, 11.08 Hz), 5.04 (dd, 
1H, H-4, J = 3.44, 10.24 Hz), 5.09 (s, 2H), 5.27 (dd, 1H, H-3, J = 1.02, 3.40 Hz), 
5.69 (d, 1H, H-1, J = 2.36 Hz), 6.34 (d, 1H, NH, J = 8.28Hz), 7.29-7.32 (m, Aryl). 
13C NMR (CDCl3) δ 16.38, 20.58, 20.65, 20.73, 46.36, 67.07, 70.84, 72.02, 92.19, 
128.50, 128.54, 128.69, 137.50, 156.72, 169.94, 169.97, 170.16, 170.57. 
IR (CDCl3) 3156.47 cm
-1 (NH), 1746.66 cm-1 (acetate carbonyls), 1649.76 cm-1
(NHCO).
Rf = 0.31 (2:1 hexane: ethyl acetate) . M.P (
oC) = N/A syrup 
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1,3,4-Tri-O-acetyl-2-N-(4-methoxybezamido)-α,β-L-fucose (10). Synthesized from 
compound 6 (0.17 g, 0.54 mmol), 4-methoxy benzoyl chloride (0.15 mL, 1.08 mmol), 
and DPPE (0.65 mmol equiv) in THF according to the general procedure described 
above. Purification by flash column chromatography (2:1, hexane: ethyl acetate) yielded 
compound 10 as a colorless syrup (0.107 g, 0.25 mmol, 47%). 
1H NMR (CDCl3) δ 1.17 (d, 3H, J = 6.24 Hz), 2.07, 2.09, 2.16 (s, 9H ), 3.71 (dq, 
1H, H-5, J = 6.42 Hz), 3.87 (s, 3H ), 4.13 (ddd, 1H, H-2, J = 2.58, 5.56, 11.08 
Hz), 5.04 (dd,  1H, H-4, J = 3.42, 10.22 Hz), 5.28 (dd, 1H, H-3, J = 0.88, 3.44 
Hz), 6.31 (d, 1H, H-1, J = 3.44 Hz), 8.09 (d, 1H, NH, J = 8.11 Hz), 7.01-7.12 (m, 
Aryl). 
13C NMR (CDCl3) δ 16.40, 20.46, 20.63, 20.69, 55.50, 66.78, 67.07, 70.84, 72.02, 
73.40, 90.37, 126.91, 132.50, 133.01, 137.73, 158.99, 168.51, 170.23, 170.57. 
IR (CDCl3) 3156.62 cm
-1 (NH), 1755.44 cm-1 (acetate carbonyls), 1605.31 cm-1
(NHCO).
Rf = 0.29 (2:1 hexane: ethyl acetate).  M.P (
oC) = N/A syrup 
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1,3,4,6-Tetra-O-acetyl-2-N-(4-methoxybenzamido)-α,β-D-glucose (13). Synthesized 
from compound 15 (0.107 g, 0.29 mmol), 4-methoxy benzoyl chloride (0.08 mL, 0.58 
mmol), and DPPE (0.65 mmol equiv) in THF according to the general procedure 
described above. Purification by flash column chromatography (2:1, hexane: ethyl 
acetate) yielded compound 13 as a colorless syrup (0.078 g, 0.16 mmol, 57%).  
1H NMR (CDCl3) δ 2.09, 2.011, 2.16 (s, 12H), 3.89 (s, 3H ), 4.09 (dd, 1H, H-6, J
= 4.80, 14.25 Hz), 4.29 (ddd, 1H, H-5, J = 2.58, 3.96, 12.45 Hz ), 5.09 (ddd, 1H,
H-2, J = 9.76, 19.57 Hz), 5.46 (dd, 1H, H-4, J = 10.00, 20.00 Hz), 5.62 (dd, 1H, 
H-3, J = 3.44, 7.86 Hz), 6.34 (d, 1H, H-1, J = 3.40 Hz), 6.79-7.25 (m, aryl group), 
8.06 (d, 1H, NH, J = 8.13 Hz).  
13C NMR (CDCl3) δ 20.38, 20.53, 20.57, 20.66, 55.72, 59.55, 67.85, 68.51, 69.88, 
71.93, 90.38, 113.78, 114.16, 126.91, 132.42, 132.85, 137.72, 159.00, 168.50, 
169.42, 169.98, 170.54. 
IR (CDCl3) 3156.62 cm
-1 (NH), 1755.44 cm-1 (acetate carbonyl), 1605.31 cm-1
(NHCO).
Rf = 0.37 (2:1 hexane: ethyl acetate).  M.P (
oC) = N/A syrup 
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1,3,4-Tri-O-acetyl-2-N-(4-chlorobenzamido)-α,β-L-fucose (11). Synthesized from
compound 6 (0.124 g, 0.39 mmol), 2-chlorobenzoyl chloride (0.10 mL, 0.78 mmol), and 
DPPE (0.65 mmol equiv) in THF according to the general procedure described above. 
Purification by flash column chromatography (2:1, hexane: ethyl acetate) yielded 
compound 11 as a pale green syrup (0.090 g, 0.21 mmol, 54 %). 
1H NMR (CDCl3) δ 1.17 (d, 3H, J= 6.24 Hz), 2.03, 2.15, 2.17 (s, 9H ), 3.71 (dq,
1H, H-5, J = 6.42 Hz), 4.13 (ddd, 1H, H-2, J = 2.58, 5.56, 11.08 Hz), 5.04 (dd, 
1H, H-4, J = 3.42, 10.22 Hz), 5.28 (dd, 1H, H-3, J = 0.88, 3.44 Hz), 6.47 (d, 1H, 
H-1, J = 4.84 Hz), 7.26-7.52 (m, Aryl), 8.03 (d, 1H, NH, J = 8.60Hz).
13C NMR (CDCl3) δ 16.40, 20.46, 20.63, 20.69, 66.78, 67.07, 70.84, 72.02, 73.40, 
90.00, 126.88, 128.87, 129.36, 131.86, 140.26, 160.20, 169.92, 170.02, 170.23, 
170.62.
IR (CDCl3) 3156.01 cm
-1 (NH), 1747.80 cm-1 (acetate carbonyl), 1645.13 cm-1
(NHCO).
Rf = 0.35 (2:1 hexane: ethyl acetate) . M.P (
oC) = N/A syrup 
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1,3,4-Tri-O-acetyl-2-N-(2-chlorobezamido)-α,β-L-fucose (12). Synthesized from
compound 6 (0.102 g, 0.32 mmol), 2-chlorobenzoyl chloride (0.08 mL, 0.64 mmol), and 
DPPE (0.65 mmol equiv) in THF according to the general procedure described above. 
Purification by flash column chromatography (2:1, hexane: ethyl acetate) yielded 
compound 12 as a colorless syrup (0.069 g, 0.16 mmol, 50 %).  
1H NMR (CDCl3) δ 1.15 (d, 3H, J= 6.44 Hz), 2.05, 2.15, 2.17 (s, 9H ), 3.70 (dq,
1H, H-5, J = 6.42 Hz), 4.12 (ddd, 1H, H-2, J = 2.58, 5.56, 11.08 Hz), 5.07 (dd, 
1H, H-4, J = 3.24, 6.48 Hz), 5.56 (dd, 1H, H-3, J = 1.10, 3.02 Hz), 5.69 (d, 1H, H-
1, J = 2.84 Hz), 8.02 (d, 1H, NH, J = 8.80Hz), 7.45-7.53 (m, Aryl). 
13C NMR (CDCl3) δ 16.39, 20.58, 20.65, 20.69, 66.78, 67.07, 70.84, 72.02, 73.40, 
92.22, 126.67, 128.56, 129.20, 130.70, 131.45, 132.40, 133.44, 134.68, 160.42, 
169.9, 170.11, 170.42, 170.80. 
IR (CDCl3) 3156.44 cm
-1 (NH), 1747.81 cm-1 (acetate carbonyl), 1651.02 cm-1
(NHCO).
Rf = 0.30 (2:1 hexane: ethyl acetate).  M.P (
oC) = N/A syrup. 
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1,3,4,6-Tetra-O-acetyl-2-N-(benzyloxyacetamido)-α,β-D-glucose (9). Synthesized from 
compound 15 (0.261 g, 0.70 mmol), benzyl chloroformate (0.20 mL, 1.4 mmol), and 
DPPE (0.65 mmol equiv) in THF according to the general procedure described above. 
Purification by flash column chromatography (2:1, hexane: ethyl acetate) yielded 
compound 7 as colorless syrup (0.026 g, 0.05 mmol, 28 %).  
1H NMR (CDCl3) δ 2.04, 2.07, 2.08, 2.16 (s, 12H), 3.89 (s, 3H), 4.09 (dd, 1H, H-
6, J = 4.80, 14.25 Hz), 4.29 (ddd, 1H, H-5, J = 2.58, 3.96, 12.45 Hz), 5.09 (ddd, 
1H, H-2, J = 9.76, 19.57 Hz), 5.10 (s, 2H), 5.46 (dd, 1H, H-4, J = 10.00, 20.00 
Hz), 5.62 (dd, 1H, H-3, J = 3.44, 7.86 Hz), 5.65 (d, 1H, H-1, J = 3.52 Hz), 6.79-
7.25 (m, aryl group), 6.43 (d, 1H, NH, J = 8.03 Hz).  
13C NMR (CDCl3) δ 20.50, 20.55, 20.64, 20.66, 46.24, 55.69, 66.94 68.48, 69.85, 
71.89, 88.79, 90.36, 126.96, 128.12, 128.22, 128.38, 128.55, 128.72, 136.26, 
137.49, 156.58, 168.49, 169.39, 169.94, 170.51. 
IR (CDCl3) 3156.37 cm
-1 (NH), 1751.56 cm-1 (acetate carbonyl), 1647.73 cm-1
(NHCO).
Rf = 0.33 (2:1 hexane: ethyl acetate).  M.P (
0C) = N/A syrup 
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3,4,6-Tri-O-acetyl-2-azidodeoxy-1-chloro-α-D-glucose (19). Compound 18 (1.0 g, 3.67 
mmol), sodium azide (0.48g, 7.33 mmol), and iron (III) chloride (1.79g, 11.02 mmol) 
were dissolved in anhydrous acetonitrile (30 mL) and the reaction mixture cooled to -30 
oC in an acetone-dry ice bath. Hydrogen peroxide (0.17 mL, 7.33 mmol) was then added 
in a dropwise fashion and the reaction was stirred vigorously at -30 oC for 5 hrs. 
Completion of the reaction was confirmed by TLC (3:1, hexane: ethylacetate) with the 
product Rf value of 0.39 for the product. The brown mixture was then extracted with  
methylene chloride (20 mL), washed with DI H2O (3 × 20 mL), dried over anhydrous 
MgSO4, filtered and evaporated in vacuo to afford brown syrup which was purified by 
flash column chromatography (3:1, hexane: ethyl acetate) yielding compound 19 as a 
light brown syrup. (0.064 g, 0.18 mmol, 5 %). 
1H NMR (CDCl3) δ 2.08, 2.10, 2.11, 2.14 (s, 9H), 3.62 ( dd, 1H, H-2, J = 3.76, 
10.56 Hz), 4.11 ( ddd, 1H, H-5,  J = 2.58, 3.96, 12.45 Hz), 4.36 ( dd, 1H, H-6, J = 
3.36,12.36 Hz ), 5.09 ( dd,  1H, H-4, J = 4.36, 10.52 Hz ),  5.78 ( dd, 1H, H-3, J =
4.98, 10.22 Hz), 6.35 ( d, 1H, H-1, J =  5.92 Hz). 
13C NMR (CDCl3) G 20.65, 20.69, 20.87, 53.38, 68.10, 68.90, 70.65, 96.50, 
169.67, 170.10, 170.52, 170.68. 
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IR (CDCl3) 2106.92 cm
-1 (N3), 1743.29 cm
-1 (acetate carbonyl). 738.81 cm-1 (C-
Cl).
Rf = 0.39 (3:1 hexane: ethyl acetate).  M.P (
0C) = N/A syrup. 
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APPENDIX 1 
1H NMR AND 13C NMR SPECTRA  
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F
igure 21. C
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 for 3,4-di-O
-acetyl-2-azidodeoxy-1-nitro-α,β-L-fucose 5.
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 spectrum
 for 3,4-di-O
-acetyl-2-azidodeoxy-1-nitro-α,β-L-fucose
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-acetyl-2-azidodeoxy-α,β-L-fucose
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6.
 
 
75 
 
F
igure 25. C
O
S
Y
 spectrum
 for 1,3,4-tri-O
-acetyl-2-azidodeoxy-α,β-L-fucose
6.
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F
igure 26. IR
 spectrum
 for 1,3,4-tri-O
-acetyl-2-azidodeoxy-α,β-L-fucose
6.
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 for 1,3,4-tri-O
-acetyl-2-N
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ido)-α,β-L-fucose
7.
 
 
78 
 
F
igure 28. 13C
 N
M
R
 spectrum
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 for 1,3,4-tri-O
-acetyl-2-N
-(benzyloxyacetam
ido)-α,β-L-fucose 8.
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F
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 spectrum
 for 1,3,4-tri-O
-acetyl-2-N
-(benzyloxyacetam
ido)-α,β-L-fucose 8.
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 spectrum
 for 1,3,4-tri-O
-acetyl-2-N
-(benzyloxyacetam
ido)-α,β-L-fucose 8.
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F
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 spectrum
 for 1,3,4-tri-O
-acetyl-2-N
-(4-chlorobenzam
ido)-α,β-L-fucose
11.
 
 
85 
 
F
igure 35. 1H
 N
M
R
 spectrum
 for 1,3,4-tri-O
-acetyl-2-N
-(2-chlorobezam
ido)-α,β-L-fucose
12.
 
 
86 
 
F
igure 36. 13C
 N
M
R
 spectrum
 for 1,3,4-tri-O
-acetyl-2-N
-(2-chlorobenzam
ido)-α,β-L-fucose
12.
 
 
87 
 
651.23
744.88
910.14
1092.50
1222.98
1380.13
1470.34
1660.05
1749.94
2255.20
2932.41
3153.14
-50
-40
-30
-20
-10  0
 10
 20
 30
 40
 50
 60
 70
 80
 90
 100
 110
 120
%T
 500   
 1000  
 1500  
 2000  
 2500  
 3000  
W
avenum
bers (cm
-1)
F
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 spectrum
 for 1,3,4-tri-O
-acetyl-2-N
-(2-chlorobenzam
ido)-α,β-L-fucose
12.
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